Pfizer beats profit estimates on demand for new drugs, COVID products, Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com

Antiviral treatment Paxlovid sales came in at $4.07 billion, also beating estimates of $3.13 billion. The company expecting significantly lower sales contributions from COVID products in the second quarter from the first quarter. Excluding COVID products, Pfizer said first-quarter revenue was mostly driven by recently acquired products, including migraine drug Nurtec ODT and sickle cell disease treatment Oxbryta., Antiviral treatment Paxlovid sales came in at $4.07 billion, also beating estimates of $3.13 billion. The company expecting significantly lower sales contributions from COVID products in the second quarter from the first quarter. Excluding COVID products, Pfizer said first-quarter revenue was mostly driven by recently acquired products, including migraine drug Nurtec ODT and sickle cell disease treatment Oxbryta., , Read More